- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01366157
Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma
Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
- To investigate the variability of expression of human geminal-center-associated lymphoma (HGAL) protein in pediatric low-risk Hodgkin lymphoma.
- To assess the variability of HGAL staining between risk groups by comparing samples from subjects enrolled in the low-risk study AHOD0431 with subject samples enrolled in AHOD0031 for intermediate-risk classical Hodgkin Lymphoma (cHL).
- To assess the variability of HGAL staining by evaluating a tissue array created from subjects with intermediate-risk cHL.
- To correlate rapid or slow early-response in the intermediate-risk group with HGAL protein expression.
OUTLINE: Paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by IHC.
Studietyp
Inskrivning (Faktisk)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
DISEASE CHARACTERISTICS:
- Diagnosed with low-risk classical Hodgkin lymphoma (cHL)
- Samples available from patients enrolled in the low-risk study COG-AHOD0431 and in the intermediate-risk cHL study COG-AHOD0031
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
|---|
|
Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL)
|
|
Variability of HGAL staining between low-risk and intermediate-risk pediatric patients with cHL
|
|
Variability of HGAL staining as assessed by tissue array in pediatric patients with intermediate-risk cHL
|
|
Correlation of rapid or slow early response in the intermediate-risk group with HGAL protein expression
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Frank G. Keller, MD, Emory Children's Center - Atlanta
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- stadium IV barndoms Hodgkin lymfom
- stadium III barndoms Hodgkin lymfom
- stadium I barndoms Hodgkin lymfom
- stadium II barndoms Hodgkin lymfom
- barndomslymfocyt dominerande Hodgkin-lymfom
- barndomslymfocytutarmning Hodgkins lymfom
- nodulär skleros i barndomen Hodgkins lymfom
- barndom blandad cellularitet Hodgkin lymfom
- childhood favorable prognosis Hodgkin lymphoma
- barndomens nodulära lymfocyter dominerande Hodgkin-lymfom
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- AHOD11B1
- COG-AHOD11B1 (Annan identifierare: Children's Oncology Group)
- CDR0000701020 (Annan identifierare: Clinical Trials.gov)
- NCI-2011-02859 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .